Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.

NCT02127307 · clinicaltrials.gov ↗

COMPLETED

Status

964

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure (HF)

Sponsor

GE Healthcare

Collaborators

[object Object]
[object Object]